Solventum Corporation (SOLV) Dividend History

Company News

• Is 3M Stock a Buy Now?

  3M, a diversified conglomerate, has faced major challenges in recent years, including sluggish sales, safety-related recalls, and billions in legal settlements. However, the company's business has gradually stabilized, and its new CEO is taking steps to improve its performance, such as accelerating R&D and new product launches. While 3M's stock is reasonably valued, its turnaround efforts could take time to bear fruit, and there may be better investment options available.

  The Motley Fool

  Featured Companies: AIG MMM
• Solventum: Q4 EPS Beats, Cash Flow Dips

  Solventum, a diversified healthcare company, reported strong Q4 2024 earnings, with adjusted EPS and revenue exceeding analyst estimates. However, the company faced challenges, including a significant decline in adjusted free cash flow and regulatory pressures. Solventum's strategic initiatives in digital healthcare solutions may offer growth opportunities, but investors should focus on how the company manages increased costs and regulatory challenges.

  The Motley Fool

  Featured Companies: MMM TMO
• Trian Comments on Solventum’s Sale of its Purification & Filtration Business

  Trian Fund Management, a major shareholder of Solventum Corporation, has commended the company's sale of its Purification & Filtration business to Thermo Fisher Scientific. Trian believes this is an important step in Solventum's value creation journey and that the business's differentiated technology and material science remain underappreciated by the market.

  GlobeNewswire Inc.

  Featured Companies: TMO
• Thermo Fisher Bets Big On Bioproduction With Solventum's Unit Deal Worth $4.1 Billion

  Thermo Fisher Scientific has agreed to acquire Solventum's Purification & Filtration business for $4.1 billion, a strategic move to expand its bioproduction capabilities. The acquired business generated around $1 billion in revenue in 2024 and is expected to generate synergies and earnings accretion for Thermo Fisher.

  Benzinga

  Featured Companies: TMO
• MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

  MediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.

  GlobeNewswire Inc.

  Featured Companies: MDWD MDXG